{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T22:33:11Z","timestamp":1776119591754,"version":"3.50.1"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"12","funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,11,29]]},"DOI":"10.1093\/cid\/cix725","type":"journal-article","created":{"date-parts":[[2017,8,11]],"date-time":"2017-08-11T07:07:44Z","timestamp":1502435264000},"page":"2105-2111","source":"Crossref","is-referenced-by-count":30,"title":["Management of Latent Tuberculosis Infection Among Healthcare Workers: 10-Year Experience at a Single Center"],"prefix":"10.1093","volume":"65","author":[{"given":"Esther","family":"Arguello Perez","sequence":"first","affiliation":[{"name":"Infectious Disease Service"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan K","family":"Seo","sequence":"additional","affiliation":[{"name":"Infectious Disease Service"},{"name":"Employee Health and Wellness Services, Memorial Sloan Kettering Cancer Center"},{"name":"Department of Medicine, Weill Cornell Medical College, New York, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William J","family":"Schneider","sequence":"additional","affiliation":[{"name":"Department of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cynthia","family":"Eisenstein","sequence":"additional","affiliation":[{"name":"Department of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arthur E","family":"Brown","sequence":"additional","affiliation":[{"name":"Infectious Disease Service"},{"name":"Department of Medicine"},{"name":"Employee Health and Wellness Services, Memorial Sloan Kettering Cancer Center"},{"name":"Department of Medicine, Weill Cornell Medical College, New York, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2017,8,17]]},"reference":[{"issue":"RR-9","key":"key\n\t\t\t\t20180306232551_CIT0001","first-page":"1","article-title":"Tuberculosis elimination revisited: obstacles, opportunities, and a renewed commitment. Advisory Council for the Elimination of Tuberculosis","volume":"48","author":"Centers for Disease Control and Prevention","year":"1999","journal-title":"MMWR Recomm Rep"},{"key":"key\n\t\t\t\t20180306232551_CIT0002","first-page":"1","article-title":"Controlling tuberculosis in the United States. Recommendations from the American Thoracic Society, CDC, and the Infectious Diseases Society of America","volume":"54","author":"Taylor","year":"2005","journal-title":"MMWR Recomm Rep"},{"key":"key\n\t\t\t\t20180306232551_CIT0003","first-page":"593","article-title":"Risk of tuberculosis infection and disease associated with work in health care settings","volume":"11","author":"Menzies","year":"2007","journal-title":"Int J Tuberc Lung Dis"},{"key":"key\n\t\t\t\t20180306232551_CIT0004","doi-asserted-by":"crossref","first-page":"488","DOI":"10.3201\/eid1703.100947","article-title":"Tuberculosis among health care workers","volume":"17","author":"Baussano","year":"2011","journal-title":"Emerg Infect Dis"},{"issue":"RR-13","key":"key\n\t\t\t\t20180306232551_CIT0005","first-page":"1","article-title":"Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care facilities, 1994","volume":"43","author":"Centers for Disease Control and Prevention","year":"1994","journal-title":"MMWR Recomm Rep"},{"key":"key\n\t\t\t\t20180306232551_CIT0006","first-page":"1","article-title":"Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care settings, 2005","volume":"54","author":"Jensen","year":"2005","journal-title":"MMWR Recomm Rep"},{"issue":"RR-6","key":"key\n\t\t\t\t20180306232551_CIT0007","article-title":"Targeted tuberculin testing and treatment of latent tuberculosis infection","volume":"49","author":"American Thoracic Society","year":"2000","journal-title":"MMWR Recomm Rep"},{"key":"key\n\t\t\t\t20180306232551_CIT0008","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1086\/422995","article-title":"Health care workers and the initiation of treatment for latent tuberculosis infection","volume":"39","author":"Gershon","year":"2004","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180306232551_CIT0009","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1378\/chest.09-0394","article-title":"Latent TB infection treatment acceptance and completion in the United States and Canada","volume":"137","author":"Horsburgh","year":"2010","journal-title":"Chest"},{"key":"key\n\t\t\t\t20180306232551_CIT0010","doi-asserted-by":"crossref","first-page":"473","DOI":"10.5588\/ijtld.12.0697","article-title":"Acceptance of treatment for latent tuberculosis infection: prospective cohort study in the United States and Canada","volume":"17","author":"Colson","year":"2013","journal-title":"Int J Tuberc Lung Dis"},{"key":"key\n\t\t\t\t20180306232551_CIT0011","first-page":"297","article-title":"Preventive treatment in tuberculosis: a statement by the Committee on Therapy, American Thoracic Society","volume":"91","author":"Runyon","year":"1965","journal-title":"Am Rev Respir Dis"},{"key":"key\n\t\t\t\t20180306232551_CIT0012","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1056\/NEJMra1405427","article-title":"Latent Mycobacterium tuberculosis infection","volume":"372","author":"Getahun","year":"2015","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180306232551_CIT0013","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1001\/archinte.166.17.1863","article-title":"Improved adherence and less toxicity with rifampin vs isoniazid for treatment of latent tuberculosis: a retrospective study","volume":"166","author":"Page","year":"2006","journal-title":"Arch Intern Med"},{"key":"key\n\t\t\t\t20180306232551_CIT0014","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1378\/chest.130.6.1712","article-title":"Enhancement of treatment completion for latent tuberculosis infection with 4 months of rifampin","volume":"130","author":"Lardizabal","year":"2006","journal-title":"Chest"},{"key":"key\n\t\t\t\t20180306232551_CIT0015","article-title":"Adherence to treatment of latent tuberculosis infection in a clinical population in New York City","volume":"14","author":"Li","year":"2010","journal-title":"Int J Infect Dis"},{"key":"key\n\t\t\t\t20180306232551_CIT0016","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1164\/rccm.200404-478OC","article-title":"Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months","volume":"170","author":"Menzies","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"key\n\t\t\t\t20180306232551_CIT0017","doi-asserted-by":"crossref","first-page":"689","DOI":"10.7326\/0003-4819-149-10-200811180-00003","article-title":"Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trial","volume":"149","author":"Menzies","year":"2008","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t20180306232551_CIT0018","first-page":"401","article-title":"Compliance, tolerance and effectiveness of a short chemoprophylaxis regimen for the treatment of tuberculosis","volume":"111","author":"Mart\u00ednez Alfaro","year":"1998","journal-title":"Med Clin (Barc)"},{"key":"key\n\t\t\t\t20180306232551_CIT0019","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0025-7753(00)71496-5","article-title":"Evaluation of 2 tuberculosis chemoprophylaxis regimens in patients infected with human immunodeficiency virus. The GECMEI Group [in Spanish]","volume":"115","author":"Mart\u00ednez Alfaro","year":"2000","journal-title":"Med Clin (Barc)"},{"key":"key\n\t\t\t\t20180306232551_CIT0020","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S0213-005X(03)72942-5","article-title":"Randomized trial of three regimens to prevent tuberculosis in HIV-infected patients with anergy","volume":"21","author":"Rivero","year":"2003","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"key\n\t\t\t\t20180306232551_CIT0021","first-page":"300","article-title":"Short-course isoniazid and rifampin compared with isoniazid for latent tuberculosis infection: a randomized clinical trial","volume":"25","author":"Geijo","year":"2007","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"key\n\t\t\t\t20180306232551_CIT0022","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1378\/chest.123.1.102","article-title":"Pyrazinamide and rifampin vs isoniazid for the treatment of latent tuberculosis: improved completion rates but more hepatotoxicity","volume":"123","author":"McNeill","year":"2003","journal-title":"Chest"},{"key":"key\n\t\t\t\t20180306232551_CIT0023","first-page":"306","article-title":"Completing tuberculosis prophylaxis in jail: targeting treatment and comparison of rifampin\/pyrazinamide with isoniazid regimens","volume":"8","author":"Lincoln","year":"2004","journal-title":"Int J Tuberc Lung Dis"},{"key":"key\n\t\t\t\t20180306232551_CIT0024","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1005136","article-title":"New regimens to prevent tuberculosis in adults with HIV infection","volume":"365s","author":"Martinson","year":"2011","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180306232551_CIT0025","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1104875","article-title":"Three months of rifapentine and isoniazid for latent tuberculosis infection","volume":"365","author":"Sterling","year":"2011","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180306232551_CIT0026","doi-asserted-by":"crossref","DOI":"10.1353\/hpu.2015.0126","article-title":"Improving treatment completion rates for latent tuberculosis infection: a review of two treatment regimens at a community health center","volume":"26","author":"Lines","year":"2015","journal-title":"J Health Care Poor Underserved"},{"key":"key\n\t\t\t\t20180306232551_CIT0027","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1093\/cid\/civ766","article-title":"Treatment for tuberculosis infection with 3 months of isoniazid and rifapentine in New York City health department clinics","volume":"62","author":"Stennis","year":"2016","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180306232551_CIT0028","first-page":"733","article-title":"Update: fatal and severe liver injuries associated with rifampin and pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society\/CDC recommendations\u2014United States, 2001","volume":"50","author":"Centers for Disease Control and Prevention","year":"2001","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key\n\t\t\t\t20180306232551_CIT0029","first-page":"735","article-title":"Update: adverse event data and revised American Thoracic Society\/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection\u2014United States, 2003","volume":"52","author":"Centers for Disease Control and Prevention; American Thoracic Society","year":"2003","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key\n\t\t\t\t20180306232551_CIT0030","first-page":"1650","article-title":"Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent Mycobacterium tuberculosis infection","volume":"60","author":"Centers for Disease Control and Prevention","year":"2011","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key\n\t\t\t\t20180306232551_CIT0031","doi-asserted-by":"crossref","first-page":"S273","DOI":"10.1093\/ofid\/ofu052.647","article-title":"939 electronic mail (email) reminders as an alternative to directly observed therapy (DOT) for the treatment of latent tuberculosis infection (LTBI) using 12 weeks of rifapentine and INH (R plus I) for healthcare workers (HCWs)","volume":"1","author":"Lacaille","year":"2014","journal-title":"Open Forum Infect Dis"},{"key":"key\n\t\t\t\t20180306232551_CIT0032","author":"National Cancer Institute"},{"key":"key\n\t\t\t\t20180306232551_CIT0033","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1001\/jama.1996.03530370051030","article-title":"Acceptance of isoniazid preventive therapy by health care workers after tuberculin skin test conversion","volume":"275","author":"Camins","year":"1996","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20180306232551_CIT0034","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0196-6553(96)90056-5","article-title":"Tuberculosis in physicians: compliance with surveillance and treatment","volume":"24","author":"Ramphal-Naley","year":"1996","journal-title":"Am J Infect Control"},{"key":"key\n\t\t\t\t20180306232551_CIT0035","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1378\/chest.113.5.1184","article-title":"Effectiveness of a nosocomial tuberculosis control program at an urban teaching hospital","volume":"113","author":"LoBue","year":"1998","journal-title":"Chest"},{"key":"key\n\t\t\t\t20180306232551_CIT0036","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1471-2458-10-28","article-title":"Referrals for positive tuberculin tests in new health care workers and students: a retrospective cohort study","volume":"10","author":"Xu","year":"2010","journal-title":"BMC Public Health"},{"key":"key\n\t\t\t\t20180306232551_CIT0037","doi-asserted-by":"crossref","first-page":"e1738","DOI":"10.7717\/peerj.1738","article-title":"Attitudes towards preventive tuberculosis treatment among hospital staff","volume":"4","author":"Pathak","year":"2016","journal-title":"PeerJ"},{"key":"key\n\t\t\t\t20180306232551_CIT0038","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1164\/rccm.200510-1667OC","article-title":"Predicting non-completion of treatment for latent tuberculous infection: a prospective survey","volume":"174","author":"Shieh","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"key\n\t\t\t\t20180306232551_CIT0039","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1164\/ajrccm\/145.1.36","article-title":"A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong Kong","volume":"145","author":"Hong Kong Chest Service; Madras\/British Medical Research Council","year":"1992","journal-title":"Am Rev Respir Dis"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/65\/12\/2105\/24267179\/cix725.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,3,6]],"date-time":"2018-03-06T23:26:50Z","timestamp":1520378810000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/65\/12\/2105\/4083488"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,17]]},"references-count":39,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2017,8,17]]},"published-print":{"date-parts":[[2017,11,29]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/cix725","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,12,15]]},"published":{"date-parts":[[2017,8,17]]}}}